Guidance for Karyopharm Therap (KPTI)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2025 | N/A | N/A | $140.00M – 155.00M | $165.50M | = Maintained | Details |
| 2024 | N/A | N/A | $145.00M – 155.00M | $152.60M | = Maintained | Details |
| 2024 | N/A | N/A | $145.00M – 160.00M | $145.30M | = Maintained | Details |
| 2024 | N/A | N/A | $140.00M – 160.00M | $157.90M | = Maintained | Details |
| Q2 2024 | N/A | N/A | $140.00M – 160.00M | $146.50M | = Maintained | Details |
| 2023 | N/A | N/A | $145.00M – 160.00M | $150.30M | = Maintained | Details |
| 2023 | N/A | N/A | $145.00M – 160.00M | $157.40M | = Maintained | Details |
| 2023 | N/A | N/A | $160.00M – 175.00M | $163.00M | = Maintained | Details |
| 2022 | N/A | N/A | $155.00M – 165.00M | $160.00M | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
